



CURE4
CYSTIC
FIBROSIS

ALL FOR THE FIGHT.

ANNUAL IMPACT REPORT
2016/17

OUR BATTLECRY.

Cure 4 Cystic Fibrosis exists to find the cure.

As individuals we are relentless and passionate in our fight, and together form a remarkable force.

We are closer to a cure than ever before, but until the day comes when no lives are lost to this disease, we must remain steadfast in our pursuit.

We are sharing stories of hope, and demonstrating our immediate impact on the advancement of this cure to inspire others to join our fight.

What we are fighting for are the funds needed to continue world-leading medical research happening in Australia. Research addressing the root cause of Cystic Fibrosis at a genetic level, with a clear path towards human clinical trials. Research that will lead to an eventual lifelong solution.

Together, and only together, are we able to take the action necessary to pursue a future free of this disease.

OUR VALUES.

IMPACTFUL

We want to give cystic fibrosis the visibility and resources it needs to accelerate a cure.

COLLABORATIVE

We form a deeper connection with our supporters to build a resilient community of like-minded go-getters, for whom we are forever grateful.

INTEGRITY

We remain uncommonly accountable and transparent when it comes to our goals and operations.

INSPIRATIONAL

We spread the power of optimism with a relentlessly warm spirit.

PASSIONATE

Our hearts, heads, talents and time are all for the fight.

CURE4
CYSTIC
FIBROSIS
ALL FOR THE FIGHT.



WHY DO WE FIGHT?

MELISSA HAYNES, CURE 4 CYSTIC FIBROSIS AMBASSADOR

The average life expectancy for someone living with Cystic Fibrosis(CF) is about 40 years, at 28 years old this statistic is not an option for Melissa Haynes.

Melly who battles Cystic Fibrosis every day, will tell you it is hard work, time consuming and something that no one should have to endure.

Each year as Melly gets older she notices that her symptoms become worse and worse, however it just pushes her to fight harder not only to try and maintain her health, but to help find a much needed cure.

Giving up is not an option for Melly - and is certainly not an option for us, Cure 4 Cystic Fibrosis are all for the fight until a cure is found.



FROM OUR CHAIRMAN

"Because of your support, this year our Foundation provided the greatest source of funding in Australia (outside of the Federal Government) toward research to develop a potential cure for cystic fibrosis airway disease."

David Coluccio, Chairman, Cure 4 Cystic Fibrosis

On behalf of the Board of Directors of Cure 4 Cystic Fibrosis I would like to thank each of the more than 1,000 individuals and organisations across Australia who contributed to 2016/17 being an extraordinarily successful year for our Foundation, and more importantly, for advancements in Australian research to cure Cystic Fibrosis (CF).

Because of your support, our Foundation provided the greatest source of funding in Australia (outside of the Federal Government) toward research to develop a potential cure for cystic fibrosis airway disease. This was achieved by supporting the work being undertaken by the Adelaide based Cystic Fibrosis Airway Research Group.

Since our formal establishment in 2009, we have fought to help ensure progress of this research. We have funded countless hours in the laboratory, additional research scientists, essential equipment, and leveraged support to build the state-of-the-art Allan Scott CF Research Laboratory in Adelaide.

In a short time we have found people and partners to fight with us to ensure this research not only continues but is accelerated, and we have equipped the research team to develop a pathway for translation toward human clinical trials.

This year we have continued to build upon this momentum, achieved outstanding financial results and delivered much that we can all be proud of.

Our partnership with the Fay Fuller Foundation was further strengthened with their commitment of \$670,000, over two years, to commence the Fay Fuller Foundation Discovery Project.

This project will, for the first time anywhere, test and measure the effectiveness of corrective gene therapy on a CF lung disease model (CF rats). If successful, it will prove that a gene therapy can prevent or halt CF lung disease. Such an outcome would have a global impact on the CF research community.

We also received a generous gift from the Hackett Foundation, which has provided a corpus of funds that will be utilised to introduce a formalised grants program in the latter part of 2017.

At the beginning of the year our board and staff also came together to redefine our strategy for the next three years. This has seen the development a new Strategic Plan based on the four pillars of:

1. Community engagement and philanthropy;
2. Scientific research and commercialisation;
3. Research advocacy and influence; and
4. Governance.

We believe that by focusing on these strategic pillars we continue to strengthen our Foundation and position ourselves to deliver further growth.

I would like to thank the members of the Board for the time, energy and professionalism they continue to bring to our Foundation. As a Board we are united in our efforts of delivering a cure for CF, and I am inspired by how firmly we are committed to this goal.

I would also like to acknowledge the continued enthusiasm, commitment and exceptional results of the researchers we support. Finally I wish to publicly express our gratitude to our wonderfully dedicated, hard-working and passionate staff without whom our success would not be possible.

Our Foundation and the research team continue to face immense challenges as the general government and philanthropic funding environment continues to be tight. However, it is always motivating to see how our shared vision across our donors, fundraisers, researchers, board and staff is delivering more and more research activity, in spite of these obstacles.

I look forward to seeing our growth in the coming year, and our continued partnerships with each of you to ensure research to cure CF is given every opportunity to succeed.



FROM OUR EXECUTIVE OFFICER

"It certainly feels as though we are uniting an army – bringing people together who will not accept the status quo, people who see the injustice of CF, and people who believe in medical research - they are giving their time, energy, skills and funds to bring us closer to a cure every day."

Linda Jones, Executive Officer

Cystic Fibrosis (CF) is an insidious disease, and while it impacts every person's life differently, the average life expectancy remains at under 40 years - some 42 years less than the Australian average.

From birth CF is unrelenting in attacking a person's body, leaving babies, young children, young adults every day fighting for their every breath.

But I am not sure if cystic fibrosis knows just who it is dealing with.

Since starting in my role as Executive Officer two years ago I have been in awe of the fighters, the CF warriors, the people who are and will continue to do whatever it takes to get us closer to a cure.

You are the inspiration and the reason that we believe that the battle to cure CF is a fight we will win!

This year we have achieved more than we could have imagined. Together we have raised the most amount of funds in the history of Cure 4 Cystic Fibrosis, and moving forward we will be able to inject more funds into research than ever before.

We have seen the Cystic Fibrosis Airway Research Group grow from strength to strength, scaling up their projects, employing new scientists, increasing the hours of existing researchers and being recognised among their peers and the community for the vital and groundbreaking work they are undertaking.

Connecting the community with the research team through our World of Hope and inaugural Research Connect events has also been received enthusiastically, and we look forward to both of these events becoming a staple on our annual calendar.

Thanks to the creative geniuses at Nation who support us pro bono, we have also rolled out a new positioning statement, look and name – we are now Cure 4 Cystic Fibrosis, and we are 'ALL FOR THE FIGHT'. It is these very words that continue to drive our philanthropic strategy which is built on the premise that to reach a cure for CF we must all work together.

This year we have also appreciated the opportunity to share stories through the media of people who are going to extraordinary lengths in their fundraising efforts to support our Foundation - stories which are inspiring even more people to join our fight.

The support of the CF community has been unwavering and continues to spread right across Australia. The Geelong Gala Ball once again raised \$50,000, and fundraisers are now being held across Victoria, Queensland New South Wales and South Australia, with our heroes challenging themselves and holding events throughout the year.


It certainly feels as though we are uniting an army - bringing people together who will not accept the status quo, people who see the injustice of CF, people who believe in medical research, and they are giving their time, energy, skills and funds to bring us closer to a cure every day.

We are also forging partnerships that see us positioned as a charity that not only has a demonstrable impact, but is sustainable and extremely cost effective. This year we invested approximately five cents from every dollar in fundraising to generate more revenue, and just 12 cents on people and infrastructure, which means the remainder is available to be further invested in research.

We are grateful to have such special donors, Ambassador Circle members, corporate partners and Trusts and Foundations who enable us to leverage their support wherever possible in pursuit of achieving our mission.

The future of research to cure CF in Australia has never looked more promising. And on behalf of every person living with cystic fibrosis that we are fighting for, I sincerely thank each of you for your generosity and continued belief in our Foundation and research to cure CF.


CURE 4 CYSTIC FIBROSIS REVENUE




The chart above includes grant funding received from the Australian Executor Trustee to fund the 'Learning for Impact' program, which the Foundation auspices.

HOW YOUR DONATIONS ARE INVESTED

For every \$1 raised or given, approximately 83 cents is available to fund existing and future research projects, 5 cents is invested back into fundraising programs to generate more revenue, and approximately 12 cents is used to ensure we have the right people, infrastructure and systems in place to support our Foundation.



INVESTMENT IN RESEARCH



ABOUT OUR FOUNDATION

ABOUT CURE 4 CYSTIC FIBROSIS

Established in 2009, Cure 4 Cystic Fibrosis aims to find a cure for CF by supporting promising areas of scientific research. To date, this has seen the Foundation invest in the research being undertaken by the Adelaide CF Airway Research Group, which is focused on a gene therapy approach to treat and potentially cure cystic fibrosis airway disease for every person living with CF.



RESEARCH WE SUPPORT

The Cystic Fibrosis Airway Research Group we support employs a world-leading gene transfer approach. They use a specially modified virus to take a correct copy of the CF gene into the airway, supplementing the defective gene that causes CF airway disease. The cell then takes over the job of producing the normal airway physiology.

The most exciting aspect of the work is that although this approach should have a long term effect on CF lung disease, it is also a potential cure. This treatment is designed to correct the airway stem cells normally present in the lung, which repair the airways and replace cells when they are damaged. This means that as new airway cells are produced by the body they will have the corrected gene within them. Success in this research project means that people living with CF airway disease will, for the first time, be able to live well and potentially be free of this disease.



WHY WE NEED A CURE

Cystic fibrosis is the most common inherited disease affecting the developed world, with one in every 2,500 children affected. It is a multi-organ disease, affecting the lungs, gut, liver, pancreas and reproductive tissues. While every person with CF has a different experience, average life expectancy remains under 40 years– approximately 42 years less than the Australian average.



There is currently no cure.

OUR BOARD

WHY WE FIGHT FOR A CURE



David Coluccio,
Chairman

We fight because it is our fight and no one will fight it for us. We must never accept no for an answer, be prepared to be ridiculed, insulted and underestimated, and then fight like hell to get the job done.



Jo Close,
Deputy Chair

I'm all for the fight to support amazing, committed researchers (our heroes!) to do their best work and profoundly transform the lives of those with cystic fibrosis.



Jacinta Connell,
Company Secretary

I believe that a world without CF is within our reach, and I am proud to stand alongside world leaders in medical research and members of the community in this passionate and tireless fight.



Mark Evans

I believe we will find a cure for CF in my lifetime; I believe we are on the right track and I absolutely believe in medical research – and I am prepared to fight for that.



Deb Hosking

Because together we will unite head on with all our abilities and work tirelessly to eliminate prevent and overcome CF.



Gregg Johnson

People affected by CF fight against the disease to survive each day and I am proud to join them in my fight to find a cure.



Lachlan Monfries

I fight for the resilient CF community and for my family who has been impacted by the disease in the past, and will be in the future.



Greg Oke

Having a son with CF drew our attention to the great burden that children, families and adults that have CF must endure. We want to do everything we can to help these people for the long term. We established Cure4CF to help and we have seen great progress towards a cure over recent years.



Jenny Paradiso

Because my friend Ruth has CF, has survived a double-lung transplant and deserves a long, healthy life.



Duane Rivett

I fight to translate the ground-breaking gene therapy research into a product which will cure CF for life.



Greg Savage

My involvement with the Cure4CF board has allowed me to meet many inspiring people living with cystic fibrosis, I believe we will find a cure for this disease and I am up for the fight to support the medical research to deliver this life changing cure.



Megan Webster-Bradman,
Deputy chair

I passionately believe that life can be better for every person with CF and that a cure is achievable if our research has the resources it needs.

OUR PEOPLE - STAFF

WE ARE ALL FOR THE FIGHT



Linda Jones,
Executive Officer

I fight because it is a battle that needs to be won, because I believe every person deserves to live a life where CF is not limiting their potential or their life expectancy.



Kerry Southwell,
Fundraising Manager

I fight because I believe gene therapy is the way forward to cure CF and I want to inspire others to become CF warriors and join the fight.

OUR AMBASSADORS



Jamie Sach - Penfolds
Global Ambassador

Jamie sach continues to show he is all for the fight against CF by working tirelessly to help find a cure for a disease that personally affects his family.



Rebecca Morse - Network
Ten Newsreader

Bec fights for a cure so all kids can live long and happy lives without struggling for breath. And so no parent will have to watch their child suffer from this cruel disease.



Mae Johnson - Cure4CF
Youth Ambassador

Our Youth Ambassador Mae who is living with CF fights for a cure by being a great role model for her peers, and by raising awareness in the community.



Angus Monfries - Port
Adelaide Football Club

Angus Monfries has every reason to fight for a cure after seeing the affects of CF on his family. Just as he does on the football field Angus brings a great deal of passion and enthusiasm to our cause.



Emmah Evans - (CF
Mummy)

When you think of the words CF Fighter Emmah Evans comes to mind. At 29 Emmah, who is living with CF, is fighting every day to stay healthy so she can raise her two children and fight for a cure.



Melissa Haynes -
Athlete

This year we welcomed Melly Haynes as an Ambassador and we could not be more proud to have her join us. Melly who is 28, and living with CF is putting all her energy and enthusiasm to help find a cure.

THERE ARE MORE THAN

70,000

PEOPLE LIVING WITH CYSTIC FIBROSIS GLOBALLY.

70,000 PEOPLE AND THEIR FAMILIES DESPERATELY
WAITING FOR A CURE.

RESEARCH IS THE ONLY SOLUTION.

HOW WE INVESTED IN RESEARCH IN 2016/2017

PEOPLE

In 2016/17 we invested more than \$130,000 in direct grants to the Cystic Fibrosis Airway Research Group. This helped cover the human resource funding gaps that many external research programs do not allow for; to travel to conferences; and to fund consumables within the laboratory. By meeting these funding needs this ensures the team are able to complete projects which will contribute to the global body of knowledge that will lead to better treatments and measurements, and one day to a lifelong cure for CF.



RESOURCES

Investing in the research team outside of wages is essential to advance the progress of this critical pathway. During the year we funded numerous professional development activities for the group to enhance their capabilities, attract additional funds and improve their capacity to manage multiple projects on the critical path.



EQUIPMENT

Through the support of a wonderful donor and the Australian Hotels Association, we were able to assist the research team purchase two essential items for the laboratory.

The first was a Bioreactor which will enable the team to upscale viral vector production. The second item was both test and human CFTR plasmids (short pieces of specially designed DNA) which are an essential ingredient needed for virus production.



THE IMPACT OF OUR INVESTMENT



FOCUS OF OUR FUNDING

The support our Foundation provides to the Cystic Fibrosis Airway Research Group (CFARG) is beyond just typical grant funding, we are committed to ensuring the research team is well resourced in people, systems and infrastructure to ensure it has the best chance of success.

Cure 4 Cystic Fibrosis is the only Foundation in Australia solely dedicated to funding a cure for cystic fibrosis, through its investment in the Adelaide based CFARG.

PROJECTS OUR SUPPORT HAS CONTRIBUTED TOWARD

Project 1. The role of airway stem cells in persisting lung gene transfer.

Project 2. CF rat colony - CF lung disease model.

Project 3. Lung and airway imaging projects.

Project 4. Delivery and assessment of stem cells to airways, to treat CF airway disease

Project 5. Upscaling gene vector production to enable sufficient capacity for current and future studies.

Project 6. Assessment of optimal lentiviral gene vector production coating, and need for airway pretreatment, for lung gene transfer.

Project 7. Assessment of optimal lentiviral gene vector construction components.

CYSTIC FIBROSIS AIRWAY RESEARCH GROUP ESTABLISH THE FIRST EVER CYSTIC FIBROSIS LUNG DISEASE MODEL (CF RAT COLONY) IN AUSTRALIASIA.

MORE THAN
18,020
RESEARCH HOURS DEVOTED TO THE PURSUIT OF A CURE FOR CYSTIC FIBROSIS AIRWAY DISEASE.

CYSTIC FIBROSIS AIRWAY RESEARCH GROUP WON THE WOMEN'S AND CHILDREN'S HEALTH NETWORK SERVICE EXCELLENCE AWARD FOR TRANSLATIONAL RESEARCH 2016/2017

CYSTIC FIBROSIS AIRWAY RESEARCH GROUP



Associate Professor David Parsons
Team Leader CFARG



Dr Martin Donnelley
Deputy Team Leader CFARG



Dr Patricia Cmielewski
Lab Manager/Animal models



Dr Nigel Farrow
Airway stem cell biology



Dr Chantelle McIntyre
CF rat breeding & studies



Dr Nathan Rout-Pitt
Vector production



Dr Juliette Delhove
Vector development



Bernadette Boog
Research admin manager



Alexandra McCarron
Phd Student



Harshavardini Padmanaban
Phd Student



Ryan Green
Phd Student



Chantelle Carpentieri
Phd Student

CYSTIC FIBROSIS AIRWAY RESEARCH GROUP

ANNUAL REVIEW

PEOPLE

- Assoc Prof David Parsons, Team Leader (0.5 FTE assigned to project);
- Dr Martin Donnelley, Deputy Team Leader (1 FTE)
- Dr Trish Cmielewski, Post-doctoral Scientist (1 FTE)
- Dr Nigel Farrow, Post-doctoral Scientist (1 FTE)
- Dr Chantelle McIntyre, Post-doctoral Scientist (0.8 FTE -1FTE as of July 2017)
- Dr Nathan Rout-Pitt, Post-doctoral Scientist (0.8FTE -1 FTE as of July 2017)
- Dr Juliette Delhove, Post-doctoral Scientist (Started Feb 0.8FTE -1 FTE as of July 2017).
- Ms Bernadette Boog, Admin/research assistant (0.4 FTE)
- PhD students: Mr Ryan Green, Ms Harsha Padmanabhan, Ms Ali McCarron.
- Honours student: Ms Chanty Carpentieri.

SIGNIFICANT ACHIEVEMENTS

Successful application to the Fay Fuller Foundation, led by the Cure 4 Cystic Fibrosis Foundation, for studies into lung gene therapy in CF rats. Funded at \$672,000 over two years.

Establishment of the first ever CF rat colony (a CF lung disease model) in Australasia.

The CFARG won the Women's and Children's Hospital Service Excellence Award for Translational Research for 2016-17.

RESEARCH ENVIRONMENT

The Cystic Fibrosis Airway Research Group is fortunate to operate within the state-of-the-art Allan Scott CF Research Laboratory, a lab dedicated to gene vector production and to support the general laboratory activities required for CF gene therapy. The group are also well supported by the Core Facilities sections of the Robinson Research Institute at the University of Adelaide. Access to the major scientific research facilities offered by the SPring-8 (Japan) and the Australian Synchrotrons provides them with unique airway research tools to support their CF gene therapy developments.

PRESENTATIONS

- A/Prof David Parsons and Dr Martin Donnelley presented research results at the North American CF Conference (Orlando, Oct 2016),
- All staff attended the Annual Robinson Research Institute conference in Adelaide, and research results were presented to the Institute members by Ms Alexandra McCarron and Ms Harsha Padmanabhan.
- A/Prof David Parsons attended and presented group abstracts at The American Society of Gene and Cell Therapy (ASGCT) meeting, (Washington, May 2017)
- A/Prof David Parsons and Dr Nigel Farrow presented research at the Thoracic Society of Australia and New Zealand scientific meeting (Canberra, March 2017)
- Dr Patricia Cmielewski presented research at the SAHMRI seminar series (Adelaide, May 2017)
- Dr Martin Donnelley and Ms Ali McCarron attended and Martin presented research at the Australian Gene and Cell Therapy meeting (Sydney, May 2017)
- Ms Harsha Padmanabhan presented her research at Australian Society for Medical Research (Adelaide, June 2017)



CYSTIC FIBROSIS AIRWAY RESEARCH GROUP

PROJECTS

THE ROLE OF AIRWAY STEM CELLS IN PERSISTING LUNG GENE TRANSFER

Researchers involved: Dr Nigel Farrow, Dr Patricia Cmielewski, Dr Martin Donnelley, A/Prof David Parsons.

Research outcomes: Animal facilities at the host institution have been updated to our required local and federal regulatory standards. Experiments are poised to begin.

Future outcomes: We expect to understand how the transduction of airway stem cells is involved in the creation of long term gene expression. These studies use reporter genes suited for both continued non-invasive analysis of overall effectiveness in the same animals, and for the identification of the locations of the transduced cells in the airway.



CYSTIC FIBROSIS LUNG DISEASE MODEL - CF RAT COLONY

Researchers involved: Dr Chantelle McIntyre, Dr Martin Donnelley, A/Prof David Parsons.

Research outcomes: We have established colonies of CF rats using the gene-editing method known as CRISPR-Cas9. The first CF animals were born mid-2017 and the colonies are growing as expected. Both the Phe508Del (the most common CF mutation in humans) and null (no CFTR present) genotypes are now available to us. Both types are expected to have spontaneous or inducible lung disease with similarities to human CF lung disease. We are currently characterizing effects of the CF mutations in these animals in preparation for testing our gene therapy approaches to treating CF lung disease.

Future outcomes: Once the CF rat colony is fully established and characterized, we hope to also provide CF animals to other Australian CF researchers and to pharmaceutical industry researchers. The current studies will provide entirely new information about the ability of our lung gene transfer techniques to prevent lung disease establishing (treatment soon after birth), or to halt lung disease that is already present later in life.

LUNG AND AIRWAY IMAGING PROJECTS

Researchers involved: Dr Martin Donnelley, Dr Patricia Cmielewski, Ms Ali McCarron, A/Prof David Parsons, Mr Ryan Green.

Research outcomes: These projects, designed to provide new ways to measure lung and airway health using novel X-ray techniques are continuing well at three sites: The Australian and Spring-8 (Japanese) synchrotrons, and at the laboratory-based X-ray system at Monash University. Examples include the first (normal) live-pig airway imaging for mucociliary transport analysis was performed at Australian Synchrotron in late 2016, and the successful normal rat imaging series to examine mucociliary transport activity was completed in June 2017 in Japan. Most recently we have captured the first paired lung-function and lung imaging data in normal rats in studies at the Australian Synchrotron; these are to be used for comparison similar data in future CF rat studies.

Future outcomes: These techniques are to be used in the testing of lung gene transfer above, and should for the first time allow the effect of gene transfer in CF rat lung to be analysed accurately and rapidly within the lung.

Ryan Green is currently writing up his PhD thesis in this area.

CYSTIC FIBROSIS AIRWAY RESEARCH GROUP

DELIVERY AND ASSESSMENT OF STEM CELLS TO AIRWAYS TO TREAT CF AIRWAY DISEASE

Researchers involved: Dr Nigel Farrow, Dr Patricia Cmielewski, Dr Martin Donnelley, A/Prof David Parsons.
Research outcomes: This project is almost complete, and has found that delivery airway stem cells that had been transduced with our lentiviral vector (containing a marker gene) into a conditioned airway could maintain gene expression for several weeks. The CFARG lentiviral gene vector was also shown in cell culture studies to be highly efficient at transducing human airway basal cells, validating future application in human studies.
Future outcomes: This project is currently being written up for publications. These findings may form the basis for a future application to investigate further how to improve longevity of gene expression.

UPSCALING GENE VECTOR PRODUCTION TO ENABLE SUFFICIENT CAPACITY FOR CURRENT AND FUTURE STUDIES

Researchers involved: Alexandra McCarron, Dr Nathan Rout-Pitt, Dr Martin Donnelley, A/Prof David Parsons
Research outcomes: After the two leading relevant bioreactor systems were trialed in our laboratory, one bioreactor system was clearly superior for our needs and has been ordered and delivered. The Bioreactor arrived in late July, and is awaiting assistance from the company to set up, before it can be used and optimized for vector production. The bioreactor will enable the research team to upscale vector production to support increased project needs
Future outcomes: Once optimized, the bioreactor will be used routinely for large volume vector production.



ASSESSMENT OF OPTIMAL LENTIVIRAL GENE VECTOR PROTEIN COATING, AND NEED FOR AIRWAY PRETREATMENT, FOR LUNG GENE TRANSFER

Researchers involved: Ms Chanty Carpentieri, Dr Nigel Farrow, Dr Martin Donnelley, A/Prof David Parsons.
Research outcomes: These studies are still in progress, as part of Ms Carpentieri's 2017 Honours project.
Future outcomes: Initial studies will be completed in late October, with long-term gene expression persistence studies planned to continue into 2018.

POTENTIAL FOR AEROSOL DELIVERY OF GENE VECTOR

Researchers involved: Ms Harsha Padmanaban, Dr Patricia Cmielewski, Dr Martin Donnelley, A/Prof David Parsons.
Research outcomes: This PhD project is nearing completion of the write up for submission.

CYSTIC FIBROSIS AIRWAY RESEARCH GROUP

ASSESSMENT OF OPTIMAL LENTIVIRAL GENE VECTOR CONSTRUCTION COMPONENTS

Researchers involved: Dr Juliette Delhove, Dr Chantelle McIntyre, Dr Martin Donnelley, A/Prof David Parsons

Research outcomes: This project is examining the effectiveness and safety of the second-generation and third-generation vector construction approaches to determine which is most effective.

Future outcomes: Findings will inform us of the optimal method of vector construction for use in our preclinical development studies.

PUBLICATIONS

Donnelley et al [<http://dx.doi.org/10.1186/s12931-017-0573-2>] | “Measuring mucociliary clearance activity in live excised large animal trachea at the Australian Synchrotron Imaging and Medical Beamline”, *Resp Research*, vol. 18:95, 2017.

H Jung, I. Lee, S. Lee, D. Parsons, M. Donnelley, “Multiple mucociliary transit marker tracking in synchrotron X-ray images using the global nearest neighbour method”, *IEEE Conference Proceedings*, Accepted for publication, 2017.

McCarron, A., Donnelley, M., McIntyre, C. & Parsons, D. Challenges of up-scaling lentivirus production and processing. *J Biotechnol* 240, 23-30 (2016).

Morgan, K.S., Petersen, T.C., Donnelley, M., Farrow, N., Parsons, D.W. & Paganin, D.M. Capturing and visualizing transient X-ray wavefront topological features by single-grid phase imaging. *Opt Express* 24, 24435-24450 (2016).

Stahr, C.S., Samarage, C.R., Donnelley, M., Farrow, N., Morgan, K.S., Zosky, G., Boucher, R.C., Siu, K.K., Mall, M.A., Parsons, D.W., Dubsky, S. & Fouras, A. Quantification of heterogeneity in lung disease with image-based pulmonary function testing. *Sci Rep* 6, 29438 (2016).

Papers under review by Journals:

Farrow, et al, “Lentiviral Transduction of Mouse and Human Airway Stem Cells”, *Human Gene Therapy*, Under Review, 2017.

Cmielewski, et al, “Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways.” Under Review.

\$1M+

TOGETHER WITH THE COMMUNITY WE RAISED MORE THAN ONE MILLION DOLLARS IN
2016/2017 TO INVEST IN RESEARCH TO CURE CYSTIC FIBROSIS.

**CURE 4
CYSTIC
FIBROSIS IS
BUILDING AN
ARMY TO
FIGHT FOR A
CURE.**

BECAUSE OF OUR COMMUNITY THIS IS A BATTLE WE ARE DESTINED TO WIN

COMMUNITY

Let's take a moment to celebrate those that run fast, walk weary, plan big, face their fears, unite their tribes and frock up all in support of a cure for CF! Our community fundraisers motivate us with just what can be achieved when people and passion unite.

MORE THAN 30 COMMUNITY FUNDRAISING ACTIVITIES AND EVENTS.

RAISING MORE THAN

\$140K

INDIVIDUALS

From our regular monthly supporters who create a sustainable income for the research group, to our donors who give so generously to our appeals, we are indebted to your belief in what we do and we thank you for ensuring the continuation of the research projects.

ALMOST 1,000 DONATIONS FROM RIGHT ACROSS AUSTRALIA.

RAISING MORE THAN

\$60K

PARTNERSHIPS

Partnerships are helping to advance the research projects we support like never before. Because of investments made by The Fay Fuller Foundation, Hacket Foundation, Australian Executor Trustee, our Ambassador Circle members and corporate partners we are forging ahead with this research by funding multiple projects, while also building the capabilities within the research team and our foundation for future growth.

IN 2016/2017 OUR PARTNERS CONTRIBUTED MORE THAN

\$815K

TO FUND MULTIPLE UPCOMING RESEARCH PROJECTS.

HOW YOUR FUNDS ARE INVESTED IN RESEARCH TO CURE CF



Annually we forecast the approximate amount of funds that will be available to award research grants. Funds are held in high interest bearing accounts until they are distributed.



The research team submits proposals for rigorous review to ensure they fit with our objective of a long term cure for every person with CF.



The grants are awarded to the research groups and each quarter they are required to submit project and milestone updates.



The results of the research projects then drive the next round of funding, coupled with a review of the achievement of goals on the critical path.

MEET SOME OF THE EXTRAORDINARY PARTNERS WHO ARE TAKING US CLOSER TO A CURE FOR CF



Melissa Haynes who is 28 and living with CF completed the 42km Adelaide marathon and raised more than \$25k for Cure4CF.



Emmah Evans (CF Mummy) held a High Tea for more than 300 guests and raised almost \$15k.

Beyond Bank Australia continue to be a valued partner supporting our Foundation as Ambassador Circle members, providing volunteer support and through their Beyond Bank charity rewards accounts.



The Springfield Help for Small Charities committee held their Christmas Cocktail event to benefit Cure4CF.



The research team supported superhero James from Queensland in Team Robins Go Red For Feb campaign.



Susan Gascoine blew us all away when she once again walked further than any of us could imagine (450km) to raise funds for Cure4CF and CFSA.

Christopher Evans of the Wounded Pelicans took our fight for a cure for CF all the way to Mount Everest, before he began the Everest Ultramarathon.



For the second year running the Geelong CF Support group raised \$50,000 at their Gala Ball attended by more than 500 guests.



Amanda Lowe and Rachel Smart once again fundraised for Cure4CF and CFSA during May and raised more than \$4,800.




Our good friends at Nation put on the war paint to help us launch our new brand by showing they too are "ALL FOR THE FIGHT".

The Lions Ride and Roses for Research have been holding a number of fundraising activities, their art show in May which showcased paintings of roses raised more than \$7,500



Anita Collins took on the City2Surf in 2016 raising funds for Cure4CF and has encouraged daughter Jordan who has CF to join her team in the 2017 event.



JOIN THE FIGHT TO CURE CF

MAKE A DONATION

Make a gift to help fund research to cure cystic fibrosis. Donations can be made at cure4cf.org.

BECOME A MONTHLY DONOR

Show you are all for the fight to cure CF with a regular donation, by giving as little as \$5 each month you can make a really big difference to the research we support.

BECOME A CORPORATE PARTNER

Our corporate partners are a valued contributor to our cause, with numerous options to set up a partnership from sponsorship, cause related marketing to workplace giving, a corporate partnership with Cure4CF will have an impact.

FUNDRAISE FOR US

Do you enjoy the thrill of the chase? Put on your running shoes and challenge yourself to be part of the cure for CF, and then ask your friends and family to sponsor you. Sign up at cure4.cf.org



HOST AN EVENT FOR US

Everyone likes a party, and a party with a purpose is always more fun. Host a fundraising event for us and we can provide you with all the tools you need to ensure it is a great success. Sign up at cure4cf.org

REMEMBER US IN YOUR WILL


leave a gift to cure4cf in your will that leave a lasting legacy through an investment in research.

ADVOCATE FOR US

Use your social profile to help us spread awareness about the need for a cure for cystic fibrosis, and the world class research being undertaken in Australia.

THE CIRCLE

Our Circle members are a part of a group of special donors who have committed to give more than \$1,000 each year, for the next five years, to research to cure CF.



AMBASSADOR CIRCLE

Our Ambassador Circle members are a high impact collective giving circle contributing more than \$12,000 each year to our Foundation. Our Ambassador Circle members play a very important role in our pathway toward a cure for CF and the sustainability of the research project.

CURE4 CYSTIC FIBROSIS

ALL FOR THE FIGHT.

IF YOU ARE INTERESTED IN A PARTNERSHIP WITH CURE 4 CYSTIC FIBROSIS OR WOULD LIKE MORE INFORMATION PLEASE CONTACT US ON 1300 131 480 OR EMAIL INFO@CURE4CF.ORG

DONOR ACKNOWLEDGEMENTS

AMBASSADOR CIRCLE MEMBERS

BEYOND BANK FOUNDATION
HOSKING FOUNDATION
MACQUARIE GROUP FOUNDATION
MCKEE
NATION CREATIVE PTY LTD
PJT HOLDINGS PTY LTD
RAW PEARLS
M & K STEELE
I & P WALL OAM

THE CIRCLE MEMBERS

A MONFRIES
L MONFRIES
M WEBSTER BRADMAN

\$1000+ DONORS

B & C CHAPMAN
G MCINTYRE
R MENZIES
F MONFRIES
D MONTGOMERY
J PARADISO
L Y PENG
K PURCELL
M & K STEELE
B M STOW SMITH

TRUSTS AND FOUNDATIONS

AFL PLAYERS ASSOCIATION CHARITY FUND
AIRROAD FOUNDATION
AUSTRALIAN EXECUTOR TRUSTEES
AUSTRALIAN HOTELS ASSOCIATION SA
FAY FULLER FOUNDATION
HACKET FOUNDATION
SPRINGFIELD HELP FOR SMALL CHARITIES

INKIND SUPPORT

FESTIVAL CITY FOOD AND LIQUOR
MCGUINNESS MEDIA
PENFOLDS
THE ROBINSON RESEARCH INSTITUTE
UNIVERSITY OF ADELAIDE
WOMEN'S AND CHILDREN'S HEALTH NETWORK

CORPORATE PARTNERS

AIR CONDITIONING & MECHANICAL CONTRACTORS' ASSN OF VIC LTD
AUSTRALIAN TAX OFFICE
BEYOND BANK AUSTRALIA
FOOTBALL FEDERATION SA
MACQUARIE MANAGEMENT WEALTH FINANCIAL
MOJOMO INSURANCE BROKERS PTY LTD
NATION CREATIVE PTY LTD
NISBET
PJT HOLDINGS PTY LTD
RAW PEARLS
RETIRED TEACHER'S ASSOCIATION
ST JAMES MART ANGLICAN CHURCH
SLAPPA THONGS PTY LTD
SYNEX AUSTRALIA
TRAVANCORE LEGAL & ADVISORY
TREMUL CONSTRUCTIONS
WOMEN'S INSOLVENCY NETWORK SA

COMMUNITY PARTNERS

65KMS FOR CYSTIC FIBROSIS - MADELEINE DALY
BAY CITY FUN RUN 2017 - DIMITY BULLEN-NICHOLAS
BAY CITY FUN RUN 2017 - EMMAH EVANS
BAY CITY FUN RUN 2017 - LORRAINE MONAGHAN
BIRTHDAY CELEBRATION - GARMINE PARADISO
BIRTHDAY CELEBRATION - JUNE BANRHARD
CITY BAY FUN RUN 2016 - PAUL CAVAIUOLO
CYSTIC FIBROSIS GEELONG INC
FEARLESS HIGH TEA - EMMAH EVANS
GO RED FOR FEB TEAM ROBINS
IN MEMORY OF KEITH BRUNT
IN MEMORY OF ROGER SCRIMSHAW
IN MEMORY OF BARRIE THOMPSON
MATILDA FUNDRAISER - MELISSA SMITH
NOOSA TRIATHLON - JOSH WALDIING
QUIZ NIGHT - MANDY LOWE & RACHEL SMART
ROSES FOR RESEARCH - WENDY HARVEY
RUNNING FOR A CAUSE - MELISSA HAYNES
SUSAN'S STRIDES 4CF - SUSAN GASCOINE
THE 2016 SUN-HERALD CITY2SURF - ANITA COLLINS
THE LION'S RIDE TO CURE CF - JASON THOMAS
THE MERIFIELDS - KELLY MERIFIELD
WOUNDED PELICANS - CHRISTOPHER EVANS

ON BEHALF OF THE CURE 4 CYSTIC FIBROSIS BOARD AND THE MEMBERS OF THE CYSTIC FIBROSIS AIRWAY RESEARCH GROUP, WE WOULD LIKE TO THANK AND ACKNOWLEDGE ALL OF THE DONORS AND COMMUNITY FUNDRAISERS WHO HAVE SUPPORTED OUR CAUSE DURING 2016/17. WHILE THERE ARE TOO MANY OF YOU NOW TO LIST INDIVIDUALLY, WE HOPE YOU KNOW THE EXTENT OF OUR GRATITUDE.

CURE 4 CYSTIC FIBROSIS FOUNDATION

FINANCIAL STATEMENTS

2016/2017

Cure4CF Foundation Limited

Financial Statements

For the Year Ended 30 June 2017

Cure4CF Foundation Limited

Contents

For the Year Ended 30 June 2017

	Page
Financial Statements	
Directors' Report	1
Statement of Profit or Loss and Other Comprehensive Income	4
Statement of Financial Position	5
Statement of Changes in Equity	6
Statement of Cash Flows	7
Notes to the Financial Statements	8
Responsible Persons' Declaration	18
Independent Audit Report	19

Cure4CF Foundation Limited

Directors' Report For the Year Ended 30 June 2017

Your Board presents their report on the Cure4CF Foundation Limited for the financial year ended 30 June 2017.

Directors

The names of each person who has been a director at any time during or since the end of the year are:

Joanna Kate Close
David Coluccio
Mark Robert Evans
Debbie Joy Hosking
Gregg Robertson Johnson
Lachlan Grey Monfries
Gregory Lancelot Oke
Jenny Paradiso
Duane John Rivett
Gregory Colin Savage
Megan Kate Webster-Bradman

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Company Secretary

The following person held the position of entity secretary at the end of the financial year:

Ms Jacinta Kate Connell LL.B., was appointed Company Secretary on 2 December 2015.

Information on Company Officers

Jo Close BBiotech (Hons), FGLF
Director
Appointed 4 December 2013
Appointed Deputy Chairwoman 7 June 2017

David Coluccio BA, MA (IntSt), MBA, GAICD
Chairman (non-executive)
Appointed director 26 May 2009
Appointed chairman 2 December 2010

Jacinta Connell LLB
Company Secretary
Appointed 2 December 2015

Mark Evans
Director
Appointed 3 August 2011

Deb Hosking
Director
Appointed 3 August 2011

Gregg Johnson CA, BCom, AssDip
MechEng
Director
Appointed 7 April 2011

Lachlan Monfries BCom, MBA
Director
Appointed 2 December 2015

Gregory Oke BAppSc, MBA, MCIPS
Director
Appointed 26 May 2009

Jenny Paradiso BA (Lib & InfoMgmt), GradDip (Comp & InfoScience)
Director
Appointed 4 June 2014

Duane Rivett MSc, MBA, RTTP
Director
Appointed 4 February 2015

Greg Savage BCom, GradDipBusAdm
Director
Appointed 7 August 2013

Megan Webster-Bradman BA, LLB (Hons), MPA
Deputy Chairwoman (Resigned 7 June 2017)
Appointed director 15 August 2015

Directors' Report

For the Year Ended 30 June 2017

Meetings of Directors

The following table sets out the number of Director's meetings held during the financial year whilst the Directors were in office and the number of meetings attended by each Director:

Officer	Number of meetings eligible to attend	Number of meetings attended
Jo Close	6	4
David Coluccio	6	6
Jacinta Connell	6	6
Mark Evans	6	6
Deb Hosking	6	5
Gregg Johnson	6	6
Lachlan Monfries	6	6
Greg Oke	6	6
Jenny Paradiso	6	4
Duane Rivett	6	5
Greg Savage	6	4
Megan Webster-Bradman	6	6

Principal Activities

Cure4CF Foundation's principal activity during the financial year was the raising of funds to support raising awareness of cystic fibrosis airway disease and research into the development of a cure.

Operating Results

The operating surplus before grant expenditure of the entity amounted to: \$901,532 (2016: \$279,806).

Dividends Paid or Recommended

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends or distributions has been made.

Significant Changes in State of Affairs

No significant change in the nature of those activities has occurred during that period.

After Balance Date Events

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the entity, the results of those operations, or the state of affairs of the entity in future financial years.

Future Developments

The entity expects to maintain the present status and level of operations and hence there are no likely developments in the entity's operations.

Environmental Issues

The entity's operations are not regulated by any significant environmental regulation under a law of the Commonwealth of a state or territory.

Cure4CF Foundation Limited

Directors' Report For the Year Ended 30 June 2017

Options

No options over issued or unissued shares or interests in the entity were granted during or since the end of the financial year and there are no options outstanding at the date of this report.

No shares or interests were issued during or since the end of the financial year as a result of the exercise of an option over unissued shares or options.

Indemnifying Officers or Auditor

The Constitution of the entity provides for every officer of the entity to be indemnified against any liability incurred by that person as an officer of the entity, and for reasonable legal costs incurred in defending an action for a liability incurred by that person as an officer of the entity.

Insurance premiums have been paid to Community Underwriting Pty Ltd for Associations Liability Insurance and Public Liability Insurance for the financial year.

No indemnities have been given during or since the end of the financial year, for any person who is or has been an auditor of the entity.

Proceedings on Behalf of the Entity

No person has applied for leave of Court to bring proceedings on behalf of the entity or intervene in any proceedings to which the entity is a party for the purpose of taking responsibility on behalf of the entity for all or any part of those proceedings.

The entity was not a party to any such proceedings during the year.

Auditor's Independence Declaration

The lead auditor's independence declaration as required under Section 307 of the *Corporations Act* 2001 for the year ended 30 June 2017 has been received and is attached to the directors' report.

Signed in accordance with a resolution of the Board of Directors.

A handwritten signature in black ink, consisting of a stylized 'D' and 'C' followed by a long horizontal line.

DAVID COLUCCIO Chairman

Dated this 27th day of September 2017

Cure4CF Foundation Limited

Statement of Profit or Loss and Other Comprehensive Income
For the Year Ended 30 June 2017

	Note	2017	2016
		\$	\$
Revenue	4	1,088,183	408,245
Other income		5,520	2,960
Administration expenses		(14,288)	(11,115)
Interest and financial expenses		(2,002)	(114)
Travel expenses		-	(294)
Marketing and events		(53,022)	(47,330)
Professional fees		(25,076)	(66,912)
Wine expenses		(10,921)	-
Employee benefits		(86,862)	(6,354)
Profit before grant expenditure		901,532	279,086
Grant expenditure		(330,763)	(275,806)
Profit before income tax		570,769	3,280
Income tax expense		-	-
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year		570,769	3,280

Cure4CF Foundation Limited

Statement of Financial Position

As At 30 June 2017

	Note	2017 \$	2016 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	5	820,822	216,479
Inventories		15,060	32,275
GST receivable		20,964	9,872
TOTAL CURRENT ASSETS		<u>856,846</u>	<u>258,626</u>
TOTAL ASSETS		<u>856,846</u>	<u>258,626</u>
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	6	35,463	28,704
Employee benefits	7	4,590	-
Grant income in advance		20,073	-
TOTAL CURRENT LIABILITIES		<u>60,126</u>	<u>28,704</u>
NET ASSETS		<u>796,720</u>	<u>229,922</u>
EQUITY			
Retained earnings		<u>796,720</u>	<u>229,922</u>
TOTAL EQUITY		<u>796,720</u>	<u>229,922</u>

Cure4CF Foundation Limited

Statement of Changes in Equity
For the Year Ended 30 June 2017

2017

	Retained Earnings	Total
	\$	\$
Balance at 1 July 2016	229,922	229,922
Adjustment	(3,971)	(3,971)
Result for the year	570,769	570,769
Balance at 30 June 2017	796,720	796,720

2016

Balance at 1 July 2015	227,492	227,492
Adjustment	(850)	(850)
Result for the year	3,280	3,280
Balance at 30 June 2016	229,922	229,922

Cure4CF Foundation Limited

Statement of Cash Flows
For the Year Ended 30 June 2017

	2017	2016
Note	\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES:		
Receipts in the course of operations	1,138,319	439,635
Payments in the course of operations	(531,974)	(412,594)
Finance costs	(2,002)	(114)
Net cash provided by/(used in) operating activities	10 <u>604,343</u>	<u>26,927</u>
Net increase/(decrease) in cash and cash equivalents held	604,343	26,927
Cash and cash equivalents at beginning of year	<u>216,479</u>	<u>189,552</u>
Cash and cash equivalents at end of financial year	5 <u>820,822</u>	<u>216,479</u>

Notes to the Financial Statements

For the Year Ended 30 June 2017

The financial report covers Cure4CF Foundation Limited as an individual entity. Cure4CF Foundation Limited is a not-for-profit Company limited by guarantee, incorporated and domiciled in Australia.

The functional and presentation currency of Cure4CF Foundation Limited is Australian dollars.

Comparatives are consistent with prior years, unless otherwise stated.

1 Basis of Preparation

In the Directors opinion, the Company is not a reporting entity since there are unlikely to exist users of the financial report who are not able to command the preparation of reports tailored so as to satisfy specifically all of their information needs. This special purpose financial report has been prepared to meet the reporting requirements of the *Australian Charities and Not-for-profits Commission Act 2012*.

The financial statements have been prepared in accordance with the recognition and measurement requirements of the Australian Accounting Standards and Accounting Interpretations, and the disclosure requirements of AASB 101 *Presentation of Financial Statements*, AASB 107 *Statement of Cash Flows*, AASB 108 *Accounting Policies, Changes in Accounting Estimates and Errors* and AASB 1054 *Australian Additional Disclosures*.

2 Summary of Significant Accounting Policies

(a) Income Tax

The Company is exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.

(b) Revenue and other income

Revenue is recognised when the amount of the revenue can be measured reliably, it is probable that economic benefits associated with the transaction will flow to the Company and specific criteria relating to the type of revenue as noted below, has been satisfied.

Revenue is measured at the fair value of the consideration received or receivable.

All revenue is stated net of the amount of goods and services tax (GST).

Sale of goods

Revenue is recognised on transfer of goods to the customer as this is deemed to be the point in time when risks and rewards are transferred and there is no longer any ownership or effective control over the goods.

Notes to the Financial Statements

For the Year Ended 30 June 2017

2 Summary of Significant Accounting Policies continued

(c) Revenue and other income continued

Grant revenue

Grant revenue is recognised in the statement of profit or loss and other comprehensive income when the entity obtains control of the grant, it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt.

Interest revenue

Interest is recognised using the effective interest method.

Other income

Other income is recognised on an accruals basis when the Company is entitled to it.

(d) Goods and services tax (GST)

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payable are stated inclusive of GST.

The net amount of GST recoverable from, or payable to, the ATO is included as part of receivables or payables in the statement of financial position.

Cash flows in the statement of cash flows are included on a gross basis and the GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

Notes to the Financial Statements

For the Year Ended 30 June 2017

2 Summary of Significant Accounting Policies continued

(e) Inventories

Inventories acquired at no cost, or for nominal consideration are valued at the current replacement cost as at the date of acquisition, which is the deemed cost.

(f) Property, plant and equipment

Each class of property, plant and equipment is carried at cost less any accumulated depreciation and impairment.

Items of property, plant and equipment acquired for nil or nominal consideration have been recorded at the acquisition date fair value.

Depreciation

Property, plant and equipment is depreciated on a straight-line basis over the assets useful life to the Company, commencing when the asset is ready for use.

At the end of each annual reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate.

(g) Financial instruments

Financial instruments are recognised initially using trade date accounting, i.e. on the date that the Company becomes party to the contractual provisions of the instrument.

On initial recognition, all financial instruments are measured at fair value plus transaction costs.

Financial Assets

Financial assets are divided into the following categories which are described in detail below:

- loans and receivables

Financial assets are assigned to the different categories on initial recognition, depending on the characteristics of the instrument and its purpose. A financial instrument's category is relevant to the way it is measured and whether any resulting income and expenses are recognised in profit or loss or in other comprehensive income.

All income and expenses relating to financial assets are recognised in the statement of profit or loss and other comprehensive income in the 'finance income' or 'finance costs' line item respectively.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers but also incorporate other types of contractual monetary assets.

After initial recognition these are measured at amortised cost using the effective interest method, less provision for impairment. Any change in their value is recognised in profit or loss.

The Company's trade and other receivables fall into this category of financial instruments.

Notes to the Financial Statements

For the Year Ended 30 June 2017

2 Summary of Significant Accounting Policies continued

(g) Financial instruments continued

Significant receivables are considered for impairment on an individual asset basis when they are past due at the reporting date or when objective evidence is received that a specific counterparty will default.

In some circumstances, the Company renegotiates repayment terms with customers which may lead to changes in the timing of the payments, the Company does not necessarily consider the balance to be impaired, however assessment is made on a case-by-case basis.

Impairment of financial assets

At the end of the reporting period the Company assesses whether there is any objective evidence that a financial asset or group of financial assets is impaired.

Financial assets at amortised cost

If there is objective evidence that an impairment loss on financial assets carried at amortised cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of the estimated future cash flows discounted at the financial assets original effective interest rate.

Impairment on loans and receivables is reduced through the use of an allowance accounts, all other impairment losses on financial assets at amortised cost are taken directly to the asset.

Subsequent recoveries of amounts previously written off are credited against other expenses in profit or loss.

(h) Impairment of non-financial assets

At the end of each reporting period the Company determines whether there is an evidence of an impairment indicator for non-financial assets.

Where this indicator exists the recoverable amount of the asset is estimated.

Where assets do not operate independently of other assets, the recoverable amount of the relevant cash-generating unit (CGU) is estimated.

The recoverable amount of an asset or CGU is the higher of the fair value less costs of disposal and the value in use.

Where the recoverable amount is less than the carrying amount, an impairment loss is recognised in profit or loss.

(i) Cash and cash equivalents

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

Notes to the Financial Statements

For the Year Ended 30 June 2017

2 Summary of Significant Accounting Policies continued

(j) Employee benefits

Provision is made for the Company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be wholly settled within one year have been measured at the amounts expected to be paid when the liability is settled.

Employee benefits expected to be settled more than one year after the end of the reporting period have been measured at the present value of the estimated future cash outflows to be made for those benefits. In determining the liability, consideration is given to employee wage increases and the probability that the employee may satisfy vesting requirements. Cashflows are discounted using market yields on high quality corporate bond rates incorporating bonds rated AAA or AA by credit agencies, with terms to maturity that match the expected timing of cashflows. Changes in the measurement of the liability are recognised in profit or loss.

(k) Adoption of new and revised accounting standards

The Company has adopted all standards which became effective for the first time at 30 June 2017, the adoption of these standards has not caused any material adjustments to the reported financial position, performance or cash flow of the Company.

Notes to the Financial Statements
For the Year Ended 30 June 2017

2 Summary of Significant Accounting Policies continued

(I) New Accounting Standards and Interpretations

The AASB has issued new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods. The Company has decided not to early adopt these Standards. The following table summarises those future requirements, and their impact on the Company where the standard is relevant:

Standard Name	Effective date for entity	Requirements	Impact
AASB 15 Revenue from contracts with customers	30 June 2019	<p>A five step process for revenue recognition with the core principle of the new Standard being for entities to recognise revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the entity expects to be entitled in exchange for those goods or services.</p> <p>Accounting policy changes will arise in timing of revenue recognition, treatment of contracts costs and contracts which contain a financing element.</p>	<p>The changes in revenue recognition requirements in AASB 15 may cause changes to the timing and amount of revenue recorded in the financial statements as well as additional disclosures. The impact of AASB 15 has not yet been quantified.</p>

Notes to the Financial Statements
For the Year Ended 30 June 2017

<p>AASB 1058 Income of NFP entities</p>	<p>30 June 2019</p>	<p>AASB 1058 supersedes all the income recognition requirements relating to private sector NFP entities, and the majority of income recognition requirements relating to public sector NFP entities, previously in AASB 1004 Contribution. The timing of income recognition depends on whether such a transaction gives rise to a liability or other performance obligation (a promise to transfer a good or service), or a contribution by owners, related to an asset (such as cash or another asset) received by an entity. AASB 1058 applies when a NFP entity receives volunteer services or enters into other transactions where the consideration to acquire an asset is significantly less than the fair value of the asset principally to enable the entity to further its objectives. In the latter case, the entity recognises and measures the asset at fair value in accordance with the applicable Australian Accounting Standard (eg AASB 116 Property, Plant and Equipment).</p> <p>Upon initial recognition of the asset, this Standard requires the entity to consider whether any other financial statement elements (called 'related amounts') should be recognised in accordance with the applicable Accounting Standard, such as: (a) contributions by owners; (b) revenue, or a contract liability arising from a contract with a customer; (c) a lease liability; (d) a financial instrument; or (e) a provision.</p> <p>If the transaction is a transfer of a financial asset to enable an entity to acquire or construct a recognisable non-financial asset to be controlled by the entity (ie an in-substance acquisition of a non-financial asset), the entity recognises a liability for the excess of the fair value of the transfer over any related amounts recognised. The entity recognises income as it satisfies its obligations under the transfer similarly to income recognition in relation to performance obligations under AASB 15. If the transaction does not enable an entity to acquire or construct a recognisable non-financial asset to be controlled by the entity, then any excess of the initial carrying amount of the recognised asset over the related amounts is recognised as income.</p>	<p>Each revenue stream, including grant agreements are currently being reviewed to determine the impact of AASB 1058. The impact of AASB 1058 has not yet been quantified.</p>
---	-------------------------	--	--

Notes to the Financial Statements

For the Year Ended 30 June 2017

3 Critical Accounting Estimates and Judgements

The directors make estimates and judgements during the preparation of these financial statements regarding assumptions about current and future events affecting transactions and balances.

These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates.

There are no critical accounting estimates and judgements required.

4 Revenue and Other Income

Revenue from continuing operations

	2017	2016
	\$	\$
Revenue		
- Ambassadors circle	69,500	-
- Community fundraising	96,048	10,370
- Community reward accounts	2,189	2,866
- Corporate donations	7,556	3,800
- Everyday hero	72,053	56,007
- Fundraising events	13,812	39,532
- General donations	14,913	14,790
- Learning for impact grant income	69,927	-
- Major gifts	170,000	122,000
- Regular giving income	36	-
- The circle income	4,200	-
- Trusts and foundations	566,238	157,900
- Wine sales	1,711	980
Total Revenue	1,088,183	408,245

Notes to the Financial Statements
For the Year Ended 30 June 2017

5 Cash and Cash Equivalents

	2017	2016
	\$	\$
Cash at bank and in hand	92,581	15,549
Short-term deposits	728,241	200,929
	<u>820,822</u>	<u>216,478</u>

Reconciliation of cash

Cash and Cash equivalents reported in the statement of cash flows are reconciled to the equivalent items in the statement of financial position as follows:

Cash and cash equivalents	<u>820,822</u>	<u>216,478</u>
---------------------------	----------------	----------------

6 Trade and Other Payables

	2017	2016
	\$	\$
CURRENT		
PAYG withholding payable	7,143	-
Superannuation payable	2,320	-
Deposits payable	-	104
Grants payable	26,000	28,600
	<u>35,463</u>	<u>28,704</u>

All amounts are short term and the carrying values are considered to be a reasonable approximation of fair value.

7 Employee Benefits

Current liabilities		
Provision for annual leave	4,590	-
	<u>4,590</u>	<u>-</u>

8 Members' Guarantee

The Company is incorporated under the *Corporations Act 2001* and is a Company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the Company. At 30 June 2017 the number of members was 12 (2016: 12).

Notes to the Financial Statements

For the Year Ended 30 June 2017

9 Contingencies

In the opinion of the Directors, the Company did not have any contingencies at 30 June 2017 (30 June 2016: None).

10 Cash Flow Information

(a) Reconciliation of result for the year to cashflows from operating activities

Reconciliation of net income to net cash provided by operating activities:		
Profit for the year	570,769	3,280
Non-cash items:		
- Retained earnings adjustment	(3,971)	(850)
Changes in assets and liabilities, net of the effects of purchase and disposal of subsidiaries:		
- (increase)/decrease in trade and other receivables	(11,092)	(5,057)
- (increase)/decrease in inventories	17,215	850
- increase/(decrease) in trade and other payables	26,832	28,704
- increase/(decrease) in employee benefits	4,590	-
Cashflow from operations	<u>604,343</u>	<u>26,927</u>

11 Related Party Transactions

The Company's related parties include its key management personnel and related entities. Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received.

Board director Jo Close is the founder and principal of research consulting firm Research Innovations. The Board approved the engagement of Research Innovations to deliver the facilitation and drafting of a five-year operational plan for the Cystic Fibrosis Airway Research Group as well as continued reporting and monitoring of progress against the plan. The amounts billed within the year ended 30 June 2017 were based on normal market rates and amounted to \$4,482.70.

12 Company Details

The registered office of and principal place of business of the company is:


Cure4CF Foundation Limited
11 Andrew Avenue
Millswood, SA, 5034

Responsible Persons' Declaration

The responsible persons declare that in the responsible persons' opinion:

- there are reasonable grounds to believe that the registered entity is able to pay all of its debts, as and when they become due and payable; and
- the financial statements and notes satisfy the requirements of the *Australian Charities and Not-for-profits Commission Act 2012*.

Signed in accordance with subsection 60.15(2) of the *Australian Charities and Not-for-profit Commission Regulation 2013*.

Director 

Director 

Dated 27 September 2017



ABN 29 191 937 410
1 Alexandra Avenue
Rose Park, SA 5067
PO Box 410
Glenside, SA 5065
P: 08 8333 7300
F: 08 8333 7301
info@sjnca.com.au
www.sjnca.com.au

Independent auditor's report

To the Members of Cure4CF Foundation Limited

Qualified Opinion

We have audited the financial report of Cure4CF Foundation Limited, which comprises the statement of financial position as at 30 June 2017, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the responsible entities' declaration.

In our opinion, except for the effects of the matter described in the *Basis for Qualified Opinion* section of our report, the accompanying financial report of Cure4CF Foundation Limited has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-Profits Commission Act 2012* (the ACNC Act), including:

- (a) giving a true and fair view of the registered entity's financial position as at 30 June 2017 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for Qualified Opinion

The Cure4CF Foundation Limited has determined that it is impracticable to establish control over the collection of cash donations prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to cash donations had to be restricted to the amounts recorded in the financial records. We therefore are unable to express an opinion on whether the recorded cash donations of Cure4CF Foundation Limited are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Directors
Stephen Noble, FCA
Mitchell Noble, CA
Adam Drabsch, CA
Joshua Walding, CA

Emphasis of Matter - Basis of Accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the registered entity's financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibility of the Responsible Entities for the Financial Report

The responsible entities of the registered entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The responsible entities' responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the responsible entities are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the responsible entities either intend to liquidate the registered entity or to cease operations, or have no realistic alternative but to do so.

The responsible entities are responsible for overseeing the registered entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the registered entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by responsible entities.
- Conclude on the appropriateness of responsible entities' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the registered entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the registered entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with responsible entities regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

SJN Chartered Accountants



Adam Drabsch
Director
Adelaide
27th September 2017



ABN 29 191 937 410
1 Alexandra Avenue
Rose Park, SA 5067
PO Box 410
Glenside, SA 5065
P: 08 8333 7300
F: 08 8333 7301
info@sjnca.com.au
www.sjnca.com.au

Auditor's Independence Declaration to the Directors of Cure4CF Foundation Limited

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2017, there have been:

- (i) no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

A handwritten signature in blue ink, appearing to read 'A S Drabsch', written over a horizontal line.

A S Drabsch
Director
Adelaide
26th September 2017

Directors
Stephen Noble, FCA
Mitchell Noble, CA
Adam Drabsch, CA
Joshua Walding, CA

CURE4
CYSTIC
FIBROSIS

ALL FOR THE FIGHT.

CONTACT US

E: INFO@CURE4CF.ORG

P: 1300 131 480

W: CURE4CF.ORG

A: PO BOX 181

UNLEY BC SA 5061